Skip to Content
Merck
CN

UC261

(±)-4-Hydroxydebrisoquin sulfate

Synonym(s):

(±)-2-Amidino-4-hydroxy-1,2,3,4-tetrahydroisoquinoline sulfate, (±)-3,4-Dihydro-4-hydroxy-2(1H)-isoquinolinecarboximidamide sulfate

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C10H13N3O · 0.5H2SO4
CAS Number:
62580-84-1
Molecular Weight:
240.27
MDL number:
MFCD09840718
UNSPSC Code:
12161501
PubChem Substance ID:
329827663
NACRES:
NA.77

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

form

solid

Quality Level

200

color

off-white

mp

267 °C

storage temp.

2-8°C

SMILES string

OS(O)(=O)=O.NC(=N)N1CC(O)c2ccccc2C1.NC(=N)N3CC(O)c4ccccc4C3

InChI

1S/2C10H13N3O.H2O4S/c2*11-10(12)13-5-7-3-1-2-4-8(7)9(14)6-13;1-5(2,3)4/h2*1-4,9,14H,5-6H2,(H3,11,12);(H2,1,2,3,4)

InChI key

AETJLQVZNVTWPH-UHFFFAOYSA-N

Application

(±)-4-Hydroxydebrisoquin sulfate can be used for the metabolic studies of debrisoquin.

Biochem/physiol Actions

CYP2D6 metabolite of debrisoquin.

Packaging

Bottomless glass bottle. Contents are inside inserted fused cone.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H315,H319,H335

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000108069
0000021005
BGBC3617V
1385690
036K3252

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

M Lanz et al.
Electrophoresis, 18(10), 1875-1881 (1998-02-12)
Using capillary zone electrophoresis with a phosphate buffer at pH 2.5 containing 50 mM heptakis-(2,3,6-tri-O-methyl)-beta-CD as chiral selector, the separation of the enantiomers of the main metabolite of debrisoquine (DEB), 4-hydroxydebrisoquine (4-OHDEB), is reported. For extraction of underivatized urinary DEB
Yueying Zhen et al.
Drug metabolism and disposition: the biological fate of chemicals, 34(9), 1563-1574 (2006-06-20)
Considerable unexplained intersubject variability in the debrisoquine metabolic ratio (urinary debrisoquine/4-hydroxydebrisoquine) exists within individual CYP2D6 genotypes. We speculated that debrisoquine was converted to as yet undisclosed metabolites. Thirteen healthy young volunteers, nine CYP2D6*1 homozygotes [extensive metabolizers (EMs)] and four CYP2D6*4
A Bozkurt et al.
Clinical pharmacology and therapeutics, 55(4), 399-401 (1994-04-01)
Debrisoquin hydroxylation polymorphism was studied in 326 unrelated healthy Turkish volunteers. Debrisoquin sulfate (10 mg) was administered to subjects, and debrisoquin and 4-hydroxydebrisoquin were determined in the 0- to 8-hour urine samples. Debrisoquin oxidation was polymorphic, with 11 subjects (3.37%;
G L Shaw et al.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 4(1), 41-48 (1995-01-01)
Previous reports of the association between the debrisoquine metabolic polymorphism and lung cancer risk have been conflicting. We examined the hypothesis that the genetically determined ability to metabolize debrisoquine identifies individuals at increased risk for lung cancer in a study
S C Mitchell et al.
Human & experimental toxicology, 13(8), 537-541 (1994-08-01)
Liver transplantation or the surgical construction of portacaval shunts may radically alter an individual's debrisoquine hydroxylation capacity. Good clinical management should encompass a full awareness of such changing needs and problems in patients who undergo hepatic surgery.
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service